Development of prospects for adjuvant treatment of malignant brain tumors in experiments on C6 glioma

Abstract

The treatment of malignant tumors and their postoperative relapses is largely limited by toxic manifestations from a large number of known chemotherapy drugs. Finding a way to reduce the toxicity of drugs while maintaining their antitumor activity is a major challenge. In this work, the highly toxic drug gemcitabine was diluted 100 and 10,000 times with ion-free water and, together with verapamil hydrochloride, at a dilution of 10,000 times, was studied for the ability, when used together, to influence the blood cell aggregation. Our previous studies with low concentrations of verapamil showed a satisfactory effect in the treatment of malignant brain gliomas. In an experiment with C6 glioma in Wistar rats, the blood cell aggregation (SPR indicators) was determined daily in vitro under the combined action of gemcitabine and verapamil at low concentrations. The daily effect of these drugs on the level of blood cell aggregation turned out to be very variable, which is an important argument against the use of chemotherapy drugs in doses that are narrowly limited by protocols. The study of the correlation coefficients between the surface plasmon resonance (SPR indicators) and the quantitative composition of cell fractions in rats after transplantation of C6 glioma made it possible to determine the scope of regenerative processes in the tumor tissue and its microenvironment, which can also make changes in the methods of tumor treatment.